Paul Daniel Regan Net Worth & Insider Trades

Paul Daniel Regan - Chief Commercial Officer, Intercept Pharmaceuticals Inc

As of February 3, 2015

What is Paul Daniel Regan's Net Worth?

The current estimated net worth of Intercept Pharmaceuticals Inc's Chief Commercial Officer, Paul Daniel Regan, is estimated to be about $13.36M . Paul Daniel Regan owns about 1,264 units of Intercept Pharmaceuticals Inc common stock. In the last 2 years at Intercept Pharmaceuticals Inc, Paul Daniel Regan has sold an estimated value of $13.35M worth.

What is Paul Daniel Regan's Past Insider Trading?

Paul Daniel Regan's largest purchase order was 20,000 units , worth over $753.8K on March 7, 2014. Paul Daniel Regan's largest sale order was 20,000 units , worth over $8.69M on March 7, 2014. In total, Paul Daniel Regan has made about 7 transactions over 2 years of their time at Intercept Pharmaceuticals Inc. Paul Daniel Regan usually trades in March, with the busiest year in 2014. The most recent transaction was a sale order of 9,847 units , worth over $1.98M on February 3, 2015.

Ticker
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1

What is Paul Daniel Regan's' Mailing Address?

  • Mailing address is C/o Intercept Pharmaceuticals, Inc. 18 Desbrosses St. New York NY 10013 NY

Intercept Pharmaceuticals Inc Executive Compensation

Name
Year
Salary
Bonus
Stock Awards
Option Awards
Other Earnings Plans or Compensations
Other Compensation
Total
Mark Pruzanski, M.D., 2020 $757,850 - $4,113,504 $1,015,996 $531,995 $7,660 $6,427,005
Mark Pruzanski, M.D., 2019 $734,292 - $4,197,742 $1,116,118 $560,265 $7,368 $6,615,785
Mark Pruzanski, M.D., 2018 $702,000 - $1,667,718 $1,705,358 $442,260 $8,623 $4,525,960
Jerome Durso, 2020 $599,524 - $2,057,016 $998,776 $231,737 $21,910 $3,908,963
Jerome Durso, 2019 $573,250 - $2,089,570 $1,238,321 $359,284 $21,368 $4,281,793
Jerome Durso, 2018 $540,800 - $1,554,326 $775,844 $292,032 $22,403 $3,185,406
Sandip Kapadia, 2020 $476,863 - $1,087,836 $528,088 $184,039 $21,910 $2,298,736
Sandip Kapadia, 2019 $464,100 - $1,001,664 $586,573 $252,935 $21,368 $2,326,640
Sandip Kapadia, 2018 $442,000 - $790,164 $393,544 $228,735 $22,403 $1,876,846
Richard Kim, 2020 $456,095 - $1,044,360 $505,128 $168,056 $79,211 $2,252,850
Richard Kim, 2019 $442,900 $202,800 $890,368 $521,398 $265,519 $76,343 $2,399,328
Lisa Bright, 2020 $480,552 - $925,704 $453,467 $240,955 $139,106 $2,239,784
Ryan Sullivan, 2020 $437,107 - $1,087,836 $528,088 - $89,942 $2,142,973
Ryan Sullivan, 2019 $445,520 - $1,471,902 $871,713 $267,089 $21,368 $3,077,592
Ryan Sullivan, 2018 $376,158 - $1,239,112 $1,190,351 $229,122 $173,437 $3,208,180
Christian Weyer, M.D., M.A.S., 2020 $486,731 - $925,704 $453,467 $170,804 $21,910 $2,058,616
No matching records found

Source: https://www.sec.gov/Archives/edgar/data/1270073/000110465921055639/tm218121-2_def14a.htm

What are Intercept Pharmaceuticals Inc's Past Insider Trades?

Intercept Pharmaceuticals Inc's most recent insider trade came on March 12, 2021 by Srinivas Akkaraju who bought 237,000 units worth $5.02M . In the last 9 years, insiders at Intercept Pharmaceuticals Inc have sold an estimated value of $1.66B and bought an estimated value of $148.73M worth of shares. Insider trading is most common in January, with the busiest year in 2019. The most active traders at the company are David Shapiro, Chief Medical Officer,  Mark Pruzanski, Director,  and Lisa Bright, President .

INTERCEPT PHARMACEUTICALS, INC. Insider Trades

Insider Names
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1